2Abraham WT,Cheng ML,Smoluk G,et al.Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Study Group.Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.Congest Heart Fail,2005,11(2):59-64.
3Cestello-Boerrigter LC,Burnett JC.The prognostic value of N-terminal proB-type natriuretic peptide.Nat Clin Pract Cardiovasc Med,2005,2(4):194-201.
4Hunt S,Abraham W,Chin M,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article.Circulation,2005,112(12):54-235.
5Nieminen M,Bohm M,Cowie M,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J,2005,26(4):384-416.
6Chung P,Hermann L.Acute decompensated heart failure:formulating an evidence-based approach to diagnosis and treatment (part ?).Mt Sinai J Med,2006,73(2):506-515.
7Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure.Drugs,2003,63(1):47-70.
8Burnett JC.Vasopoptidase inhibition:a new concept in blood pressure management.J Hypertens Suppl.1999,17(1):37-43.
9Luchner A,Burnett JC,Jougasaki M,et al.Evaluation of brain antriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population.J Hypertens,2000,18(8):1121-1128.
10Baxter GF.The natriuretic peptides.Basic Res Cardiol,2004,99(2):71-75.
